News
XGN
1.360
-4.82%
-0.069
Weekly Report: what happened at XGN last week (0408-0412)?
Weekly Report · 4d ago
Weekly Report: what happened at XGN last week (0401-0405)?
Weekly Report · 04/08 09:50
Weekly Report: what happened at XGN last week (0325-0329)?
Weekly Report · 04/01 09:50
Weekly Report: what happened at XGN last week (0318-0322)?
Weekly Report · 03/25 09:51
Buy Rating Affirmed for Exagen on Strong Financials and Strategic Growth Initiatives
TipRanks · 03/20 09:56
Exagen’s Challenge: Strengthening Financial Controls to Restore Confidence and Secure Growth
TipRanks · 03/19 06:00
Exagen’s Strong Q4 Performance and Positive Outlook Justify Buy Rating
TipRanks · 03/18 23:05
XGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q4 2023
Exagen reported earnings per share of -31 cents. The company reported revenue of $13.77 million. Exagen's revenue was 19.07% better than the analyst estimate of $11.56 million for the quarter. The stock is down 1.7% today.
Investorplace · 03/18 16:52
Exagen reports Q4 results
Exagen reports Q4 results. Q4 total revenue was $13.8 million. Full year net loss was $23.7 million, on revenue of $52.5 million. Exagen is a biotechnology company with a focus on cancer treatment. The company's stock is down 7% in the last week.
Seeking Alpha · 03/18 15:27
Canopy Growth, Outlook Therapeutics, Immuneering among healthcare movers
Healthcare On the Move: Canopy Growth, Outlook Therapeutics, Immuneering among healthcare movers. S&P 500 Health Care Sector +0.1% to 1692.1. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index.
Seeking Alpha · 03/18 14:00
Exagen Inc reports results for the quarter ended in December - Earnings Summary
Exagen Inc reports results for the quarter ended in December. Revenue rose 7.2% to $13.77 million from a year ago. The company reported a quarterly loss of $5.57 million. Exagen Inc shares had fallen by 18.6% this quarter.
Reuters · 03/18 13:31
Exagen Q4 GAAP EPS $(0.31) Beats $(0.43) Estimate, Sales $13.77M Beat $11.56M Estimate
Exagen reported quarterly losses of $0.31 per share. The company reported quarterly sales of $13.77 million. Exagen beat the analyst consensus estimate of $11.56 million by 19.07%. The company also reported a 62.65 percent increase in sales from the same period last year.
Benzinga · 03/18 12:03
*Exagen Sees 2024 Rev $54M >XGN
Dow Jones · 03/18 12:02
*Exagen 4Q Loss $5.57M >XGN
Dow Jones · 03/18 12:00
Press Release: Exagen Inc. Reports Strong Fourth -2-
All forward-looking statements are qualified in their entirety by this cautionary statement. Exagen Inc. Undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date of this release. The company's quarterly and year-on-year results for the quarter ended December 31, 2018 are reported on a constant currency basis.
Dow Jones · 03/18 12:00
*Exagen 4Q Loss/Shr 31c >XGN
Dow Jones · 03/18 12:00
Press Release: Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results. Record total revenue of $52.5 million for the full-year 2023. Record 137,650 AVISE(R) CTD tests performed to date since launch. Total revenue for the fourth quarter of 2023 was $13.8 million. Exagen is a leading provider of autoimmune testing solutions.
Dow Jones · 03/18 12:00
*Exagen 4Q Rev $13.8M >XGN
Dow Jones · 03/18 12:00
Earnings Scheduled For March 18, 2024
Niu Techs (NASDAQ:NIU) is expected to report earnings for its fourth quarter. Embraer is estimated to report quarterly earnings at $0.53 per share on revenue of $2.00 billion. Companies Reporting Before The Bell include System1 and Nano Labs.
Benzinga · 03/18 09:57
Weekly Report: what happened at XGN last week (0311-0315)?
Weekly Report · 03/18 09:50
More
Webull provides a variety of real-time XGN stock news. You can receive the latest news about Exagen Inc. through multiple platforms. This information may help you make smarter investment decisions.
About XGN
Exagen Inc. is a provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision-making. The Company has developed and is commercializing a portfolio of testing products, under its AVISE brand. It commercially launched its testing product, AVISE CTD, which enables differential diagnosis for patients presenting with symptoms indicative of a variety of connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The comprehensive nature of AVISE CTD allows for the testing of various relevant biomarkers in one convenient blood draw. Included in AVISE CTD is its proprietary AVISE Lupus test, which enables the diagnosis of systemic lupus erythematosus (SLE) based on levels of erythrocyte bound C4d (EC4d) and B cell C4d (BC4d); along with anti-nuclear antibodies (ANA) and double-stranded DNA antibodies (ds-DNA). AVISE Lupus provides rheumatologists and their patients with sensitive and specific results.